Stem cell clinic firms often come and go rather quickly, but a few like Regenexx have persisted. It’s even become a brand name. I’ve been writing here on The Niche for more than twelve years about stem cell clinics. Regenexx has been around that whole time. Along with its founder Dr. Chris Centeno. Patients have […]
Fact-checking Regenexx: reviews, data & cost Read More »
The news of the week relates to an interim clinical trial report from gene-editing firm Editas on its CRISPR trial for a form of vision loss. On to that in a minute. What have you been reading the past week? Below, I include our weekly list of recommended reads. However, first I wanted to give
The Niche weekend reads: Editas mess, The Niche updates, papers Read More »
The push for de-extinction of woolly mammoths is a perfect example of when one notion can be both fun and a rotten idea. You can’t let the coolness push you down a bad path. You can see my new YouTube video covering the main points of this post from our YouTube channel further down. Please
Why De-extinction of Woolly Mammoths is Still a Bad Idea Read More »
This blog is called The Niche so publications on the stem cell niche often catch my eye even if that’s not something my own lab directly works on much. So today’s recommended reads will start with two papers on the stem cell niche. The first one focused on the niche gone wrong. The stem cell
Recommend reads: stem cell niche, Georgia & FTC on clinics, more Read More »
I recently found concerning SEC filings from the biotech Cryo-Cell about a deal it has with a Duke team for infusions of children with unproven umbilical cord cells. This turns out to be a $58 million deal. It relates in a major way to a Duke compassionate use or expanded access program (EAP) that already had raised
FDA should freeze Duke EAP & probe $58 million Cryo-Cell deal linked to it Read More »
The other day I gave a talk in part about stem cell hype and mentioned as an example how the idea of already doing stem cell therapy for autism seems so misguided to me now. On the whole, in my view there are major downsides and risks for autistic kids whose parents are already having
Fact-checking stem cell therapy for autism: still a risky idea Read More »
Let’s start off today’s recommended reads with the topic of life extension. No controversy there, right? This comes to mind because of a new preprint from BioViva, Liz Parrish, and George Church. I’m hoping to cover this on our Stem Cell Channel on YouTube. Gene therapy and life extension research The preprint is entitled, “New
Weekly reads: life extension & BioViva, clinics & anti-vax, axolotls, systemic CRISPR Read More »
ViaCyte released encouraging data just now on a patient with implanted stem cell-derived pancreas-like device whose diabetes improved. You can read more about this in the Endpoints piece that I linked to in the previous sentence. Stem cells for diabetes; the ViaCyte update The idea of stem cells for diabetes has been more on my
Quick reaction to milestone ViaCyte data on a diabetes patient Read More »
The idea of stem cell therapy for diabetes is both exciting and in a way practical. By that I mean that there’s a good common sense foundation here. The idea of stem cell therapy for diabetes What do I mean? If medical researchers can replace lost beta cells in the pancreas using stem cell-produced beta
Stem cell therapy for diabetes updates: expected IPO, CRISPR, new pubs, more Read More »
Professor Joanne Kurtzberg’s clinical work at the Duke Autism Center on umbilical cord blood for autism and cerebral palsy (CP) involves a partnership with a publicly-traded cord blood banking firm called Cryo-Cell. Kurtzberg is also the Medical Director at the firm. In addition they have intellectual property in this area. The Duke team’s efforts, including
Duke & Cryo-Cell plan big clinic for unproven infusions of kids Read More »